Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes

Drug Metabolism and Disposition

Volumn 26, Issue 3, 1998, Pages 261-266

  Nakajima, Miki ^b   Inoue, Tsuyoshi ^b   Shimada, Noriaki ^b   Tokudome, Shogo ^b   Yamamoto, Toshinori ^b   Kuroiwa, Yukio ^a  

^a SHOWA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; COMPLEMENTARY DNA; CYTOCHROME P450; ERYTHROMYCIN; INDOMETACIN; MEPHENYTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGENASE; SULFAPHENAZOLE; TOLBUTAMIDE; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ALKYLATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INDOMETHACIN; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; OXIDOREDUCTASES, O-DEMETHYLATING; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFAPHENAZOLE; TOLBUTAMIDE; TUMOR CELLS, CULTURED; WARFARIN;

EID: 0031920705     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alván G, Orme M, Bertilsson L, Ekstrand R and Palmér L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18:364-373.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Birkett DJ, Mackenzie PI, Veronese ME and Miners JO (1993) In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14:291-294.
4. TB (CYP2C) controls mefenamic acid elimination. Clin Pharmacol Ther 55:139.
5. Butler MA, Iwasaki M, Guengerich FP and Kadlubar FF (1989) Human cytochrome P450PA (P-450 IA2), the phenacetin O-deethylase, is primary responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
6. Chan TYK and Critchley JAJH (1994) Adverse interaction between warfarin and indomethacin. Drug Safety 11:213-214.
7. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T and Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with (S)-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
8. Duggan DE, Hogans AF, Kwan KC and McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181:563-575.
9. Gonzalez FJ (1992) Human cytochromes P450: problems and perspectives. Trends Pharmacol Sci 13:346-352.
10. Harman RE, Meisinger MAP, Davis GE and Kuehl FA Jr (1964) The metabolites of indomethacin, a new antiinflammatory drug. J Pharmacol Exp Ther 143:215-220.
11. Johannesen KAM and Depierre JW (1978) Measurement of cytochrome P-450 in the presence of large amounts of contaminating hemoglobin and methemoglobin. Anal Biochem 84:725-732.
12. 5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Jpn J Pharmacol 24:195-203.
13. Kaminsky LS and Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
14. TB (CYP2C). Experientia (Basel) 48:A7.
15. LeClyse EL, Ribadeneira MD, Diamond S, Forster J, Huang S-M, Madan A, Caroll K and Parkinson A (1996) Induction of CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A by various drugs and prototypical inducers in primary cultures of human hepatocytes. Proc Int Soc Study Xenobiotics 10:196.
16. TB (CYP2C): the major elimination pathway of (±)-ibuprofen in humans. Clin Pharmacol Ther 55:208.
17. Leemann TD, Transon C, Bonnabry P and Dayer P (1993a) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19:189-195.
18. TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci (Wash DC) 52:29-34.
19. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M and Schary W (1974) Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 53:1607-1617.
20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Mason RW and McQueen EG (1974) Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate in vitro. Pharmacology 12:12-19.
22. Meier UT, Kronbach T and Meyer UA (1985) Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem 151:286-291.
23. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 37:1137-1144.
24. Miners JO, Veronese ME and Birkett DJ (1994) In vitro approaches for the prediction of human drug metabolism. Ann Rep Med Chem 29:307-316.
25. Mungall D, Wong YY, Talbert RL, Crawford MH, Marshall J, Hawkins DW and Ludden TM (1984) Plasma protein binding of warfarin: methodological considerations. J Pharm Sci 73:1000-1001.
26. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
27. 13C]warfarin pseudoracemates in man. J Clin Invest 65:746-753.
28. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
29. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
30. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF and Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42.
31. Rolan PE (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128.
32. Romkes M, Faletto MB, Blaisdell JA, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255.
33. Terashima K, Takai S, Usami Y, Adachi T, Sugiyama T, Katagiri Y and Hirano K (1996) Purification and partial characterization of an indomethacin hydrolyzing enzyme from pig liver. Pharm Res 13:1327-1330.
34. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO and Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175:1112-1118.
35. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.
36. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:23-43.